Table 2 Second-Line Treatment Regimens in the Chemotherapy Group (n = 89)
Second-Line Therapy Received, n (%) | |
|---|---|
Gemcitabine | 28 (31.5) |
Vinorelbine | 24 (26.9) |
Docetaxel | 22 (24.7) |
Others | 7 (7.9) |
Carboplatin/gemcitabine | 2 (2.2) |
Atezolizumab | 2 (2.2) |
Carboplatin/docetaxel | 2 (2.2) |
Carboplatin/vinorelbine | 1 (1.1) |
Pembrolizumab/docetaxel | 1 (1.1) |